lipoprotein (HDL)-cholesterol including reduced subclass HDL2 particles and raised serum apolipoprotein B concentrations. Xanthoma and xanthelasma may relate to low lipoprotein lipase activity (10–12).

On a similar theme further questions that need clarity are what about other skin ‘lipid’ stigmata and cardiovascular risk? For example eruptive and tuberous xanthomata are associated with chylomicron syndrome and type III dyslipoproteinaemia, respectively, and acanthosis nigricans and skin tags are possible features of insulin resistance states (13).

It is unlikely that we will ever know the Mona Lisa’s carotid IMT but it makes sense as Bergman (8) has suggested to determine plasma lipoprotein levels in patients with xanthelasma and to assess them for cardiovascular risk.

Disclosure

The author has stated that he has no interests which might be perceived as posing conflict or bias.

M. Crook
Clinical Biochemistry,
University Hospital Lewisham,
London, UK
Email: martin.crook@doctors.org.uk

References

1 Chan CC, Lin SJ, Hwang JJ et al. Xanthelasma is not associated with increased risk of carotid atherosclerosis in normolipidaemia. Int J Clin Pract 2008; 62: 221–7.
2 Dequeker J, Muls E, Leenders K. Xanthelasma and lipoma in Leonardo da Vinci’s Mona Lisa. Isr Med Assoc J 2004; 6: 505–6.
3 Parker F, Olland GE. Experimental xanthoma: a correlative biochemical, histologic, histochemical and electron microscopic study. Am J Pathol 1968; 53: 537–65.
4 Bergman R, Kasif Y, Aviram M et al. Normolipidaemic xanthelasma palpebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages and plasma lipid peroxidation. Acta Derm Venereol 1996; 76: 107–10.
5 Ribera M, Pinto X, Argimon JM et al. Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma. Am J Med 1995; 99: 485–90.
6 Segal P, Insull W Jr, Chambless LE et al. The association of dyslipoproteinaemia with corneal arcus and xanthelasma: the Lipid Research Clinics Program Prevalence Study. Circulation 1986; 73 (Suppl.): 108–18.
7 Menotti A, Mariotti S, Seccareccia F et al. Determinants of all causes of death in samples of Italian middle-aged men followed up for 25 years. J Epidemiol Community Health 1987; 41: 243–50.
8 Bergman R. Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol 1998; 37: 343–9.
9 Tursen U, Eskandari G, Kaya TI et al. Apolipoprotein E polymorphism and lipoprotein compositions in normolipidaemic xanthelasma patients. J Eur Acad Dermatol Venereol 2006; 20: 260–3.
10 Watanabe A, Yoshimura A, Wakasugi T et al. Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis 1981; 38: 283–90.
11 Douste-Blazy P, Marcel YL, Cohen L et al. Increased frequency of apo E-ND phenotype and hyperapolobetalipoproteinaemia in normolipidaemic subjects with xanthelasmas of the eyelids. Ann Intern Med 1982; 96: 164–9.
12 Bates MC, Warren SG. Xanthelasma: clinical indicator of decreased levels of high-density lipoprotein cholesterol. South Med J 1989; 82: 570–4.
13 Crook M. Skin tags are associated with the atherogenic lipid profile. J Clin Pathol 2000; 53: 873–4.

EDITORIAL

Sexual health as a portal to men’s health: a problem turned around into an opportunity

The prevalence of genitourinary problems and associated health concerns is high in middle-aged and older men. A representative survey among men in Australia over the age of 40 years indicated that 34% reported one or more reproductive health disorder (1). There is a belief that men, compared with women, make less use of health services. This was not confirmed in the above study. About 88% of men in this study had consulted a health professional in the past 12 months, and health service utilisation increased with age. However, the research showed also that sexual and reproductive health problems are often not explicitly discussed with a health professional. Clinicians, while often seen as the primary source of contact for reproductive health problems, are often reluctant to initiate discussions with older patients about sexual health (2). In our view many opportunities to improve ageing men’s health are thus not utilised. We propose a view here that genitourinary (including sexual) health is a ‘portal’ to men’s health.

Symptoms of genitourinary problems, such as erectile dysfunction (ED) and lower urinary tract symptoms of genitourinary problems are associated with the metabolic syndrome and type 2 diabetes
symptoms (LUTS) (3) are significantly associated with the metabolic syndrome and type 2 diabetes mellitus. The main components of the metabolic syndrome are abdominal obesity, insulin resistance, hypertension and hyperlipidaemia, all of which are etiological factors of ED. The metabolic syndrome and one of its consequences, type 2 diabetes mellitus, are, in turn, associated with lower-than-normal serum testosterone (T) levels (late onset hypogonadism). It is noteworthy that late onset hypogonadism is frequently symptomatic. In men 45 years or older surveyed in 130 primary care practices in the USA, the presence of one or more symptoms occurred in 66% of men deemed hypogonadal based on their T levels(4).

The relationship between the metabolic syndrome and type 2 diabetes mellitus and hypogonadism is probably bidirectional. A large degree of obesity and hyperinsulinism suppresses production of T, but low T levels predict the metabolic syndrome and type 2 diabetes mellitus. So, there is a close relationship between ailments frequently occurring in the ageing male (ED, LUTS, visceral obesity, cardiovascular disease and diabetes mellitus) on the one hand and hypogonadism on the other. This close relationship probably indicates that late onset hypogonadism is an expression of poor health, as may be concluded from a recent study. Low testosterone levels were associated with increased mortality in male veterans (5), but this association was not confirmed in another study (6). This is as yet not sufficient evidence to treat all ageing men with hypogonadism with T. Lifestyle changes are associated with improvement in sexual function in about one-third of obese men with ED at baseline. Weight loss and increased physical activity appeared to have a favourable effect on erectile and endothelial functions in obese men (7,8). The Massachusetts Male Aging Study has estimated the frequency of ED progression and remission among ageing men, and assessed the relation of progression/remission to demographics, socioeconomic factors, comorbidities and modifiable lifestyle characteristics. Natural remission and progression occur in a substantial number of men with ED. Age and body mass index were associated with progression and remission of ED. The association of body mass index with remission and progression, and the association of smoking and health status with progression, offer potential avenues for facilitating remission and delaying progression. The benefits of such interventions for overall men’s health may be far reaching and confirm the position that ED is a portal to men’s health (9).

Treatment of ED when associated with hypogonadism may entail T administration (10) and these interventional studies may provide an opportunity to assess benefits, yield, and justification of T administration on the closely interrelated ailments of ED and the metabolic syndrome of which epidemiologically hypogonadism is a correlate. The first results of T administration to elderly men show that this may lead to improvement of both ED and elements of metabolic syndrome (11) but the administration of T to men with diabetes mellitus is disappointing (12).

Shabsigh (13) have argued that ED can calculate men’s health risks. Elements in the calculation of health risks (hypertension, diabetes, angina or hyperlipidaemia) in men presenting with ED are: health status on a scale of 1–7 (1 = excellent, 7 = poor), waist size, severity of ED, presence/absence of a sexual partner. The calculation produces scores of ranges of 1–7. If the score is 1.5–2.5 = medium risk (30–59% probability); ≥ 2.5 = high risk (≥ 60% probability of having the condition) and < 1.5 = low risk (< 30% probability).

In conclusion, physicians confronted with elderly men with genitourinary problems are in a unique position to address general health questions of the patient. A holistic approach will not only benefit the presenting complaint but improve the general health and well-being of the patient.

Disclosure

RS is a consultant/advisor to Bayer Schering Pharma, Lilly, Pfizer, Indevus, Boehringer Ingelheim, Auxilium, Johnson & Johnson, American Medical Systems and Coloplast.

R. Shabsigh,1 S. Arver,2 K. S. Channer,3 I. Eardley,4 A. Fabbri,5 L. Gooren,6 A. Heufelder,7 H. Jones,8 S. Meryn,9 M. Zitzmann10
1Division of Urology, Maimonides Medical Center, Columbia University, Brooklyn, NY, USA
2Center for Andrology and Sexual Medicine, Karolinska University Hospital/Huddinge, Stockholm, Sweden
3Royal Hallamshire Hospital, Sheffield, UK
4Department of Urology, St James University Hospital, Leeds, UK
5Università di Roma Tor Vergata, Rome, Italy
6Endocrinology, Vrije Universiteit medical center, Amsterdam, The Netherlands
7Endocrine Clinic & Research Unit, Munich, Germany
8University of Sheffield Medical School, Sheffield, UK
9Institute for Medical Education, University of Vienna, Vienna, Austria
10Institute of Reproductive Medicine, Münster, Germany

Physicians confronted with elderly men with genitourinary problems are in a unique position to address general health questions.
References
1 Holden CA, McLachlan RI, Pitts M et al. Men in Australia Telephone Survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet 2005; 366: 218–24.
2 Gott M, Hinchliff S, Galena E. General practitioner attitudes to discussing sexual health issues with older people. Soc Sci Med 2004; 58: 2093–103.
3 Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 2005; 29: 310–6.
4 Mulligan T, Frick MF, Zuraw QC et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762–9.
5 Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660–5.
6 Araujo A, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Intern Med 2007; 167: 1252–60.
7 Esposito K, Giugliano F, Di Palo C et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291: 2978–84.
8 Esposito K, Marfella R, Ciutola M et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440–6.
9 Travison TG, Shabsigh R, Araujo AB et al. The natural progression and remission of erectile dysfunction: results from the Massachusetts Male Aging Study. J Urol 2007; 177: 241–6; discussion 6.
10 Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006; 3: 382–404; discussion 7.
11 Kapoor D, Malkin CI, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239–50.
12 Basu R, Dalla Man C, Campioni M et al. Effects of two years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance and postprandial glucose turnover in elderly men. Diabetes Care 2007; 30: 1972–8.
13 Shabsigh R, Sand M. Erectile dysfunction and men’s health: developing a comorbidity risk calculator. J Sex Med 2006; 62(suppl 6): 4 (abstract MP-05-035).